Comparative Pharmacology
Head-to-head clinical analysis: AN DTPA versus SODIUM IODIDE I 131.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AN DTPA versus SODIUM IODIDE I 131.
AN-DTPA vs SODIUM IODIDE I 131
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
AN-DTPA (pentetate calcium trisodium) is a chelating agent that binds to and removes heavy metals, such as plutonium, americium, curium, and other transuranic elements, from the body. It forms stable complexes with these metals, which are then excreted via the kidneys.
Sodium iodide I 131 is a radioactive isotope that emits beta particles and gamma rays. It is taken up by the thyroid gland via the sodium-iodide symporter and incorporated into thyroid hormones. The beta radiation causes local destruction of thyroid tissue, reducing hormone production and treating hyperthyroidism or thyroid cancer.
1 gram by intravenous injection or infusion daily for 5 consecutive days, starting immediately after the end of radiotherapy.
For thyroid ablation or therapy of thyrotoxicosis: 100-200 mCi (3.7-7.4 GBq) orally as a single dose. For diagnostic imaging: 5-10 μCi (0.185-0.37 MBq) orally.
None Documented
None Documented
Terminal elimination half-life: approximately 1.5-2 hours in patients with normal renal function. Extended significantly in renal impairment (up to 24 hours in anuria).
Physical half-life: 8.02 days. Effective half-life in euthyroid patients: ~5-7 days, but reduced to ~3-5 days in hyperthyroidism due to increased turnover. In thyroid cancer with remnant ablation, effective half-life may be longer (up to 8 days) due to reduced clearance.
Renal: >95% as unchanged drug via glomerular filtration. Biliary/fecal: <5%.
Primarily renal; approximately 90% excreted in urine within 72 hours, with the remainder eliminated via feces (biliary-fecal route, <10% in bile).
Category C
Category C
Radiopharmaceutical
Radiopharmaceutical